Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference

Sep 27, 2018

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

Sep 25, 2018

Fortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 (Copper Histidinate) for Menkes Disease in Molecular Therapy: Methods & Clinical Development

Sep 12, 2018

Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

Sep 06, 2018

Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018

Sep 04, 2018

Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Aug 30, 2018

Mustang Bio to Participate in September Investor Conferences

Aug 30, 2018

Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Aug 14, 2018

Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Aug 13, 2018

Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer

Aug 13, 2018
RSS
  • Prev
    • 1...
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    • 58
    • 59
    • 60
    • 61
    • ...71
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap